Menopause
Postmenopausal years — sustained low estrogen, accelerated bone and muscle loss, altered metabolism. Typically 50+.
Cofactor + NAD+ substrate + GH-axis (adjunct to HRT) · 3 phases · guided multi-peptide program with decision criteria and add-to-stack handoff.
What changes during this transition
Postmenopausal women face accelerated bone loss, sarcopenia, central fat gain, declining muscle mass, increased cardiovascular risk, sleep fragmentation, and cognitive shifts. HRT (when appropriate) is the primary intervention for the hormonal component. Peptides relevant here focus on lean-mass preservation, sleep architecture, recovery, and the longevity-cellular-aging axis. GH-axis peptides (CJC-1295, ipamorelin, tesamorelin) become more relevant as endogenous GH/IGF-1 decline accelerates with age.
Important caveat
Cardiovascular and bone-density risk should be tracked alongside any peptide protocol — DEXA scans and lipid panels matter more in this window than peptide adjustments. Coordinate with a clinician familiar with menopausal medicine.
Peptides editorially relevant to menopause
9 peptides from the library — each evidence-tiered honestly.
- CJC-1295Tier 3
GHRH analog
Long-acting GHRH analog often paired with a GHRP. Strong PK data in humans; outcome data is limited.
- IpamorelinTier 3
GHRP / ghrelin mimetic
Selective GH-releasing peptide with minimal cortisol or prolactin elevation in early studies. Human outcome evidence is limited.
- TesamorelinTier 1
GHRH analog
FDA-approved for HIV-associated lipodystrophy. Off-label use for general fat loss is meaningfully less supported.
- MK-677 (Ibutamoren)Tier 2
Non-peptide ghrelin mimetic (small molecule)
Orally bioavailable small molecule that elevates GH and IGF-1. Multiple human RCTs confirm the hormone effect; clinical-outcome benefits are far less settled.
- EpithalonTier 4
Synthetic tetrapeptide (AEDG)
Synthetic tetrapeptide claimed to extend telomere length and reduce all-cause mortality in older adults.
- MOTS-cTier 3
Mitochondrial-derived peptide
Mitochondrial-encoded peptide with strong rodent data on insulin sensitivity, endurance, and metabolic health.
- DSIPTier 3
Sleep-related neuropeptide (nonapeptide)
Discovered in 1977. A handful of small clinical studies in the 1980s for sleep, narcolepsy, and opioid withdrawal. The evidence is thin, old, and largely unreplicated. Tier 3.
- PT-141 (Bremelanotide)Tier 1
Melanocortin receptor agonist
FDA-approved as Vyleesi for premenopausal HSDD. Off-label use for male erectile function and on-demand libido is widespread but supported by far thinner evidence.
- BPC-157Tier 3
Gastric pentadecapeptide
Extensively studied in rodents for tissue healing across tendon, gut, vascular, and CNS injury models. Human evidence is essentially absent — community framing far outpaces the data.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.